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ric cancers. Methods: Current oncology PIPs were manually extracted from the 
EMA website for the study period 2007-2014. Primary variables included: indication, 
applicant, decision, decision date, and date of expected completion. Indications for 
approved PIPs were classified into five categories: brain tumors, diagnostics, leuke-
mias/lymphomas, side effects, and solid tumors. Results: A total of 105 PIPs were 
found; 36 of which were waivers, and 69 of which were approved. The study found 
that 39% (27) of approved PIPs were indicated for solid tumors, including melanomas 
and malignant tumors; 30% (21) of approved PIPs were indicated for leukemias or 
lymphomas; 17% (12) of approved PIPs were indicated for chemotherapy-induced 
side effects, such as anti-nausea and neuotropenia medications; 12% (8) of approved 
PIPs were indicated for brain tumors; and one oncology diagnostic PIP was also 
approved. The ramp-up of the PIP program was significant. PIPs approved in 2013 
and the first half of 2014 accounted for 54% (37) of all PIPs approved during the study 
period. ConClusions: Approved PIPs covered a wide range of pediatric cancers, 
and the number of approved PIPs increased significantly over time. While the ramp-
up of the PIP program indicated that it was successful in promoting research in 
this area, serious concerns remained regarding the feasibility of the program. For 
example, there were currently four trials planned for completion between 2015-
2020 for extremely rare high grade gliomas. This limitation may compromise the 
integrity of the PIP program.
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objeCtives: Little information is available on the patterns of chemotherapy regi-
mens administered for the treatment of ovarian cancer (OC) in the Netherlands. 
The objective for this study was to describe current chemotherapy patterns for OC 
in the Netherlands and to evaluate survival outcomes following subsequent lines 
of chemotherapy. Methods: Data from the Eindhoven Cancer Registry, including 
data on all newly diagnosed cancer patients, was linked to the PHARMO Database 
Network including, among other things, information on in- and outpatient drug use. 
Patients diagnosed with primary OC between January 2000 and December 2010 were 
selected. First and subsequent chemotherapy regimens were defined as the start of 
a different (combination of) chemotherapeutic agent (s) or a gap > 42 days (or > 91 
or > 183 days in sensitivity analysis) between two treatment cycles. Results: Of 
the included OC patients, 70% received chemotherapy as initial treatment. Detailed 
chemotherapy data were available for 261 patients, who had a mean age of 63 (SD 
12) years. Pathological tumor stage was known for 77% of patients, of whom 11%, 
55% and 17% of patients had disease stage II, III, and IV, respectively. In first line 
chemotherapy, 76% of patients received platinum/taxane doublet chemotherapy. 
Of the 161 patients receiving second line chemotherapy, platinum-containing 
chemotherapy was received by 63% of patients (101 of whom 13 received platinum 
monotherapy). In third line chemotherapy this was 51% (53 patients). At least eight 
lines of chemotherapy were identified in 12 cases. Median survival as from diag-
nosis was 46 months. After second line chemotherapy, median survival remained 
14 months. ConClusions: This study provides detailed information on the type 
of chemotherapy regimens administered to OC patients at initial diagnosis and 
during follow-up and the survival following the various chemotherapy regimens.
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objeCtives: Erythropoietin stimulating agents (ESAs) are useful drugs for treating 
chemotherapy related anemia to reduce the number of blood transfusions. However, 
there were unrecognized toxicities of ESAs. These toxicities were finally recognized 
in 2007 when the FDA issued a black box warning for ESAs. The objective of this 
study is to determine the effect of the FDA black box warning on ESA use pat-
terns and associated outcomes in insured, low-income cancer patients in South 
Carolina. Methods: The merged South Carolina Central Cancer Registry-Medicaid 
dataset was used to determine the trend of ESA use from 2001-2010. Female Breast, 
Colorectal and Non-Small Cell Lung cancer patients were identified from the reg-
istry. Of those, their chemotherapy status was identified along with ESA use from 
Medicaid medical claims. The major outcome measures were claims for use of ESAs 
after chemotherapy and the blood transfusion rate. Logistic regression was used as 
a quantitative method to determine if the likelihood of receiving ESA treatment was 
reduced after FDA black box warning. Results: Among 1,645 patients treated with 
chemotherapy from 2002-2010, the proportion of chemotherapy patients receiving 
ESAs decreased from 56.47 % before the black box warning to 23.16% after black box 
warning (p < 0.001). The blood transfusion rate per year during 2002-2007 remained 
around 10-15% and increased to 31% in 2009. The likelihood of ESA use was reduced 
by 63% after black box warning issued by FDA after adjusting for demographic and 
clinical variables. ConClusions: The black box warning may have been effective 
in reducing overall ESA utilization in cancer patients taking chemotherapy.
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to reimbursements, causing a significant growth in costs. Expenses for oncology in 
2003-2011 increased by 718% (from € 15.4 million to € 125.7 million). In December 
2011, a cost/QALY threshold was introduced to legislation, creating a barrier to 
the inclusion of oncology drugs to the Reimbursement list. Following adoption of 
this legislation, of the 12 drugs registered by the EMA, only 3 oncology drugs were 
included to the List during 2012-2014. Uncategorized drugs are available only for a 
limited number of patients by way of individual exceptions, or by participation in 
clinical trials. ConClusions: In Slovakia, the willingness to pay for an additional 
unit of health was anchored in legislation, which greatly limited the availability of 
innovative oncological treatment. The health system in Slovakia needs to intro-
duce efficient and transparent mechanisms that enable the treatment of oncology 
patients in line with the latest medical findings, while keeping expenses for treat-
ment within economic possibilities.
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BiOPharmaCeuTiCals aCrOss sOme emea markeTs
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objeCtives: Across geographies, approval, pricing and reimbursement of phar-
maceuticals take place under varying timelines with different outcomes. There 
are some countries that may obtain access to new pharmaceuticals through early 
access schemes. Breakthrough and innovative products that are thought to have a 
profound impact on current standard of care are often eligible for quicker routes to 
access. This research sought to investigate how these schemes worked, where they 
were prevalent, and the outcomes of such schemes. Methods: The research was 
conducted through in-depth interviews with payers and clinicians across 10 EMEA 
markets. Results: Of the 10 markets studied, 5 countries were identified to have 
either easier or quicker routes to access for new biopharmaceuticals (e.g., ATU in 
France and Algeria, law 648/96 in Italy, non-formulary access in Saudi Arabia, and 
the “white list” in Norway). Most often, these routes were reserved for products with 
orphan indications or products that were believed to significantly impact current 
standard of care. If pharmaceutical companies opt for the streamlined route, there 
are often significant restrictions imposed on the product, as well as a reduction 
in volume. If companies elect for the standard route to approval and reimburse-
ment, the review process is often more rigorous, however, the decision is likely 
more permanent and the volume of product is larger. Frequently, if products opt 
for the faster route to access, this will serve as additional evidence for getting the 
product reimbursed at a later date for use in a wider population. ConClusions: 
New pharmaceutical products that are likely to dramatically change the treatment 
landscape or are active in orphan diseases should take advantage of these schemes. 
Physicians grasp at the opportunity to use efficacious products as early as possible 
and companies need to leverage the opportunity for streamlined access to products.
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objeCtives: Lung cancer has a continuously bad prognosis in terms of survival 
and quality of life, usually because of late detection of malignancies. Given an 
expected increase in the incidence, overall mortality will increase. Early detec-
tion and efficient diagnostic planning may offer additional gain in survival. The 
diagnostic pathway for patients with suspected lung cancer is characterized by a 
cascade of different imaging and diagnostic modalities. The main objective of this 
study is to estimate the health economic impact of diagnostic procedures and the 
expected gain by volume-doubling time on low-dose CT as biomarker in suspected 
lung cancer (NELSON protocol). Methods: A state-transition model is created to 
simulate the pathway of lung cancer diagnostic procedures, including x-ray, diag-
nostic CT, PET-CT, bronchoscopy, mediastinoscopy and more. Hospital registries 
and data from the National Cancer Registry were used to estimate the amount of 
diagnostic procedures in a cohort of lung cancer patients. Systematic literature 
search was performed to estimate the diagnostic performance of different modali-
ties. Patient cohort is defined and the pre-test probability for malignancy is esti-
mated through the Swensen criteria. Probabilistic sensitivity analysis is performed 
using Monte Carlo Simulations. Results: Diagnostic procedures for patients with 
suspected lung cancer can count up to almost € 3000 per patient. Pathway was 
modeled in a microsimulated cohort through Swensen criteria, leading to a mean 
chance of malignancy of 40%. Costly steps in the pathway include cervical medi-
astinoscopy and mutation analysis. Inclusion of NELSON protocol can lead to a 
reduction in costs. Decision making per patient can reduce overuse of diagnostic 
modalities. ConClusions: The diagnostic procedure for suspected lung cancer 
patients is a costly pathway and can be improved with use of the NELSON screening 
protocol or personalized selection of diagnostic procedures.
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hOW suCCessful have PediaTriC iNvesTigaTiON PlaNs BeeN iN 
sTimulaTiNg researCh fOr PediaTriC CaNCers?
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objeCtives: The European Pediatric Medicine Regulation was created in 2007 to 
encourage further drug development for pediatric diseases, by requiring pharma-
ceutical companies to submit pediatric investigation plans (PIPs) when submitting 
the marketing application for a new drug. The objective of this study was to deter-
mine how successful this legislation had been in stimulating research in pediat-
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to identify investments required to establish a national breast cancer program 
across KSA.
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objeCtives: To assess co-relation of GDP per capita (purchasing power parity) on 
pharmaceutical pricing. Methods: Based on empirical research, 18 drugs were 
selected and grouped into seven therapeutic categories: (1) Blood Based Disorders; (2) 
Cardiovascular Disorders; (3) Inflammatory Disorders; (4) Oncology; (5) Respiratory 
Disorders (only fluticasone); (6) Diabetes; and (7) Viral Diseases Price per unit (mg, IU, 
and U; at ex-factory level) data was collected from IHS PharmOnline International 
(POLI) Database across 41 countries (Australia, Austria, Belgium, Brazil, Bulgaria, 
Canada, China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, India, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, 
Morocco, The Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, 
Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Turkey, UK, and United 
States) from 2007 to 2012. Prices were converted into Euros on a yearly exchange 
rate basis and adjusted for inflation. Additionally, GDP data was collected from 
World Bank for the same period. We fit the regression equation for the log price per 
unit (dependent variable), log GDP per capita, generic status, strength, percentage 
of population aged 65 and above, an indicator for the US market, and year (inde-
pendent variables) as follows: Y (Price per Unit) = α + ∑ β i * Xi + ε . Results: eltrom-
bopag (-0.977+.131, n= 160), filgrastim (-4.08+. 347, n= 1420), etanercept (-.253+. 227, 
n= 870), adalimumab (2.52+. 128, n= 306), cetuximab (-.325+.166, n= 203), pazopanib 
(-3.78+.164, n= 111), fluticasone (.559+.559, n= 108), sitagliptin (-4.00+.215, n= 413), 
Stocrin (-12.75+.803, n= 556) and Truvada (-5.08+.157, n= 168) had statistically sig-
nificant GDP (PPP) coefficients at the 0.01 level, whereas Tasigna, bevacizumab, 
dabigatran, rivaroxaban, exenatide, liraglutide, saxagliptin, and interferon alpha 
were not significant at 0.01 level. ConClusions: Our model finds varying degrees 
of co-relation between GDP per capita (PPP) and price per unit. Nonetheless, sitag-
liptin, cetuximab, filgrastim, Stocrin, Truvada, and adalimumab exhibited highest 
co-relation; they are thus most differentially priced.
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objeCtives: Chemotherapy-induced FN is associated with increased morbid-
ity and mortality and frequently leads to hospitalization. This analysis aimed to 
describe FN-HCRU in patients hospitalized for FN in Bulgaria. Methods: Eleven 
Bulgarian centres contributed to this international, retrospective, observational 
study conducted in Bulgaria, Czech Republic, and Slovakia. Adult patients with ST 
or HM receiving the chemotherapy leading to the first (= index) FN event between 
01/2009 and 09/2012 and at least one confirmed FN event were enrolled. FN-specific 
HCRU parameters included infection prophylaxis and treatments, G-CSF use, other 
prophylactic medication, specific interventions and investigations, and FN-related 
hospitalizations. Results: 156 Bulgarian patients were analysed (ST= 64, HM= 92); 
median age: 55.5 years, ECOG 0-2: 81%. All of ST and 79% of HM had one FN episode 
(≥ 3 episodes: 6%) with a mean (SD) number of FN-related hospital days of 6.6 (4.75) 
and 7.7 (4.79). Chemotherapy was completed as planned in 38% of ST and 87% of HM 
patients. In the index cycle, G-CSF was predominantly administered as treatment 
(86%, 48%), with a minority used as primary prophylaxis in ST (5%) and HM (30%) 
patients. In the index cycle, FN-related investigations were conducted in 83% of ST 
patients (207 investigations) and 78% of HM patients (324 investigations), mostly 
blood tests (ST= 83%, HM= 68%) or imaging (ST= 14%, HM= 20%). FN-related interven-
tions were conducted in 70% each of ST (220 interventions) and HM patients (196 
interventions), mainly IV fluids (ST= 64%, HM= 56%) or blood transfusions (ST= 17%, 
HM= 27%). In ST, 6 of 7 (86%), in HM 2 of 10 (20%) deaths during the observational 
period were FN-related. ConClusions: The data showed considerable HCRU in 
patients experiencing FN in Bulgaria, with frequent lack of G-CSF prophylaxis 
observed, particularly in ST patients. Improved G-CSF targeting may reduce FN 
and lower associated HCRU.
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objeCtives: To examine patient characteristics, health care resource utiliza-
tion (HRU) and medical costs of patients who were untreated for neuroendocrine 
tumors (NETs). Methods: Using a US administrative claims database, commer-
cially-insured adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209. xx) 
or pancreatic islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 
12/31/2010 were identified (the first observed diagnosis date as the index date). 
Patients were required to have 6-month pre-index and 12-month post-index enroll-
ment. Untreated patients were defined as those receiving neither surgical nor 
medical treatments in the 12-month follow-up period. Descriptive analysis was 
objeCtives: NAT for eBC have potential benefits in reducing tumor size, permit-
ting breast conservation, identifying effective adjuvant regimens, and providing 
prognostic information. This study investigated the characteristics of eBC patients, 
real-world utilization patterns of NAT, and health care costs from diagnosis to 
primary surgery (neoadjuvant phase) using a US claims database. Methods: A 
cohort from the IMS PharMetrics Plus database included female patients, aged 
18+, with the first (index) breast cancer (BC) diagnosis (ICD-9-CM 174. x, 233.0) 
between July 2006 and September 2012, primary surgery (mastectomy or lumpec-
tomy) after index, continuous enrollment from 180 days before index (pre-index) 
to 90 days after surgery, no pre-index diagnosis for BC or other primary cancer, 
and no secondary malignancy from pre-index to surgery. Systemic therapies used 
by this cohort in neoadjuvant phase were assumed as NAT. Patients with eBC 
trastuzumab use were presumed HER2+. Results: Of 57,032 eligible eBC patients 
(median age= 56), 2,011 (3.5%) received NAT. Patients who received NAT had pri-
mary surgery in a median of 166 days after index diagnosis vs. 21 days for patients 
who did not receive NAT. Among patients receiving NAT, 485 (24.1%) had trastu-
zumab, with TCH (docetaxel, carboplatin, trastuzumab) and ACTH (doxorubicin, 
cyclophosphamide, a taxane, trastuzumab) most frequently used (49.5% and 
26.2%, respectively). FEC regimen (5-flurouracil, epirubicin, cyclophosphamide) 
was used by only 5.6% trastuzumab users. From 2007 to 2011, there was a 46% 
increase in proportion of trastuzumab use in NAT users (19.6% to 28.6%). Among 
eBC patients receiving NAT, trastuzumab users had a higher monthly health care 
cost in neoadjuvant phase ($17,425 vs. $11,422) than those without trastuzumab 
use; however, the out-of-pocket spending by patients ($389 vs. $370) was simi-
lar. ConClusions: Based on these real-world data, neoadjuvant use of systemic 
therapies was infrequent. Among the patients with HER2+ eBC, TCH and ACTH 
were the most frequently used neoadjuvant regimens, consistent with their use 
in the adjuvant setting.
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objeCtives: The use of off-label medication is restricted by government in some 
countries, because using off-label anticancer drugs has some concerns about its 
efficacy and toxicity. HIRA (Health Insurance Review & Assessment Service) has the 
process for the assessment and control for the off-label use of anticancer drugs in 
South Korea. We would introduce the controlling for the off-label use of anticancer 
drugs and evaluate the trend of off-label use in anticancer drugs. Methods: Since 
Dec. 2006, HIRA has permitted off-label uses for which there is adequate evidence 
for the efficacy, toxicity, and cost effectiveness. We collected the patient’s medi-
cal record data (briefly recorded response rate, major adverse effects. etc) which 
updated every year from hospital. We defined 37 cancers (36 cancers, other cancer) 
and preparative regimens of Hematopoietic stem cell transplantation. We calculated 
the number of approved off-label regimens by year and cancer type, and the regimen 
of the most widely used. Results: From Dec. 2006 to 2013, total 203 off-label regi-
mens were approved their use in 63 hospitals (number of cumulative cases: 16,596). 
From 2006 to 2012, the number of approved off-label regimen was increased (1, 3, 
3, 14, 39.37, 67, respectively). In 2013, only 38 regimens were approved. Compared 
with the other cancer, non-Hodgkin lymphoma (30 regimens, 15%), ovarian cancer 
(10 regimens, 5%), and CLL (10 regimens, 5%) have many off-label regimens. The 
regimens: “< 3 weekly> S-1 + cisplatin for gastric cancer” was the most widely used 
regimens (59 hospitals, number of cumulative cases: 2,283). ConClusions: The use 
of off-label anticancer drugs has been increased in South Korea since 2006. These 
results suggest that the development of new drugs and the more clinical trials 
should be needed in cancer disease.
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objeCtives: To develop a national breast cancer (BC) screening program through 
phased regional expansion using an advanced investment decision support 
simulation model informed by real world data in the Kingdom of Saudi Arabia 
(KSA). Methods: An agent-based modeling simulation (ABMS) tool will represent 
the KSA female population, BC burden and existing health system and project 
impact of infrastructure investment options. Data are drawn from existing sources 
including census, registries and health surveys; phased studies will generate real 
world data on the outcomes of new clinical interventions. In Phase 1, a mobile BC 
screening program was deployed in Riyadh with three mobile clinics equipped 
with appropriate technology and medical staffing with the goal to screen at least 
10,000 women during 2012-2014 and establish a care pathway for accurate diag-
nosis. The modeling and phased studies will guide the national program develop-
ment by evaluating the impact of investments on BC screening rates, outcomes 
and economic value. Results: The Phase 1 Riyadh program screened 12,877 
females and established a care pathway model leading to 83 confirmed BC diagno-
ses (rate: 6.4 per 1000). Data visualization plotting breast cancer disease prevalence 
and mammogram installed base identified areas of high need and low resources in 
the regions of Riyadh, Hafr Al-Baten, Eastern, Al-Ahsa and Al-Jouf. The ABMS model 
to be developed will evaluate the impact of investment scenarios encompassing 
expansion of existing facilities and manpower, development of new radiology 
centers, and implementation of additional mobile programs. ConClusions: 
The Riyadh program revealed higher rate of breast cancer in the region than pre-
viously reported, emphasizing the need to ensure access for accurate diagnosis 
and create a national program. Data visualization readily identified regions for 
prioritized expansion. Real world data will continue to inform the ABMS model 
